Renal Anemia

Dedication. Introduction; E.A. Friedman. Correcting Anemia Slows Renal Disease Progression; E.A. Friedman. Does Treatment With EPO Improve RBS Survival? C.D. Brown, et al. Has The Best Route of Administration of Epoetin Been Established? A. Besarab, R.J. Schmidt. Is Renal Anemia Management Determined by Science or Reimbursement Regulations? C. Charytan. When Does Anemia Impact The Heart In Chronic Disease? A. Levin. Improvements in Anemia Management with Darbepoetin Alfa, A New Erythropoiesis Stimulating Protein; J.S. Lindberg. Normalizing Hematocrit in Renal Failure: Dangerous or Desirable? J.C. Macdougall. Do Race, Gender or Mode of Dialysis Modulate Erythropoietin Response? B.G. Delano. Are Uremic Inhibitors of Erythropoiesis Clinically Relevant? O. Ifudu. Do ACE inhibitors Limit Response to EPO and Should EPO be continued in Patients with Sepsis or Fever? M.O. Salifu. Is Secondary Hyperparathyroidism a Significant Cause of Renal Anemia? O. Ifudu. Is Long-term Intravenous Iron Therapy Risky? W.L. St. Peter. Anemia and Erythropoietin Therapy in Kidney Transplant Recipients: Where Are The Data? O. Ifudu. Intravenous Iron Treatment: A Comparison of Available Drugs; S. Fishbane. Epilogue; E.A. Friedman.